Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies

In this multicollaborator evaluation, large declines in enrollment, major protocol deviations, dropouts, and severe toxicity during the acute phase of the pandemic all returned to pre-COVID-19 levels by 2021-2022. These findings highlight the impact of the temporary disruption to trial conduct during the pandemic's peak, but suggest that pandemic-related procedural flexibility did not result in long-term reduced data quality. Sponsors and regulators should consider broader adaptation of trial flexibilities moving forward.

Authors

Institutions

Publication Details

Journal
JCO oncology advances.
Published
2025-03-01
DOI
https://doi.org/10.1200/oa-25-00021
Citations
3
Primary Topic
COVID-19 and healthcare impacts
Type
article
Field-Weighted Citation Impact
3.14
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies

Keith T. Flaherty, Elizabeth Garrett‐Mayer, Suanna S. Bruinooge, Therica M. Miller et al.
3 citations
JCO oncology advances.
COVID-19 and healthcare impacts
3.14
article

Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies

Keith T. Flaherty, Elizabeth Garrett‐Mayer, Suanna S. Bruinooge, Therica M. Miller, Mark Stewart, Laura A. Levit, Hillary S. Andrews, Daniel B. Kimball, Caroline Schenkel, Beverly Canin, Brittany A. McKelvey, Joseph M. Unger, Adedayo A. Onitilo
article en
3 citations

Abstract

In this multicollaborator evaluation, large declines in enrollment, major protocol deviations, dropouts, and severe toxicity during the acute phase of the pandemic all returned to pre-COVID-19 levels by 2021-2022. These findings highlight the impact of the temporary disruption to trial conduct during the pandemic's peak, but suggest that pandemic-related procedural flexibility did not result in long-term reduced data quality. Sponsors and regulators should consider broader adaptation of trial flexibilities moving forward.

JCO oncology advances.Vol. 2(2)
American Society of Clinical Oncology (US), Johnson & Johnson (United States) (US), Children's National (US), The King's College (US), Massachusetts General Hospital (US), Fred Hutch Cancer Center (US), Marshfield Clinic Weston Center (US), Tisch Hospital (US), Breast Cancer Options, Tisch Cancer Institute, Friends of Cancer Research (US)
Openalex Percentile: Top 8%
COVID-19 and healthcare impacts
3.14
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.